What are the epidemiology, genetic basis, histopathology, and clinical manifestations of metachromatic leukodystrophy?

Metachromatic Leukodystrophy: Comprehensive Overview

Metachromatic leukodystrophy (MLD) is an autosomal recessive lysosomal storage disease caused by arylsulfatase A (ARSA) enzyme deficiency, leading to sulfatide accumulation and progressive demyelination of the central and peripheral nervous systems, with an overall birth prevalence ranging from 0.16 to 4.1 per 100,000 live births depending on population studied 1, 2.

Epidemiology

MLD is a panethnic disorder with significant geographic and ethnic variation in incidence 1:

• General population estimates: Birth prevalence ranges from 1:40,000 (Sweden, Washington State) to 1:170,000 (Germany) for the most common late infantile subtype 1
• Recent systematic data: Birth prevalence per 100,000 live births ranges from 0.16 in Japan to 1.85 in Portugal 2
• Polish population studies suggest substantial underdiagnosis, with predicted birth prevalence of 4.1/100,000 based on carrier rates versus only 0.38/100,000 diagnosed cases 3

High-risk populations with dramatically elevated incidence 1:

• Habbanite Jewish population: 1:75
• Alaskan Eskimos: 1:2,500
• Navajo Indians: 1:6,400

Clinical subtype distribution: Late-infantile and juvenile MLD account for at least two-thirds of cases in most studies, with late-infantile representing 40-60% of all MLD cases 1, 2.

Genetic Basis

Primary Genetic Defect

MLD is caused by mutations in the ARSA gene encoding arylsulfatase A (E.C. 3.1.6.8), resulting in deficient enzymatic activity 1, 4. Over 140 disease-relevant mutations have been identified 1.

Common mutations account for approximately 50-60% of disease alleles 1, 4:

• c.459+1G>A: Accounts for ~25% of disease alleles (splice donor site mutation, "null allele")
• p.P426L: Accounts for ~25% of disease alleles ("R allele" with residual activity)
• p.I179S: Accounts for ~12.5% of disease alleles ("R allele" with residual activity)

Genotype-Phenotype Correlations

Mutations are classified into two functional groups 1:

1. "Null alleles" (e.g., c.459+1G>A, c.1204+1G>A): Complete loss of enzymatic activity → more severe phenotypes
2. "R alleles" (e.g., p.P426L, p.I179S): Residual catalytic activity up to 5% of normal → milder phenotypes

Important caveat: The p.I179S mutation is associated with predominantly psychiatric presentations and may be particularly underdiagnosed 3.

Alternative Genetic Causes

Two other biochemical defects produce MLD or MLD-like phenotypes 1:

• Saposin B deficiency: Deficiency of sphingolipid activator protein saposin B (OMIM# 249900)
• Multiple sulfatase deficiency (MSD): Mutations in SUMF1 gene (OMIM# 272200), presenting with demyelination plus ichthyosis and mucopolysaccharidosis features

Critical Diagnostic Pitfall: ARSA Pseudodeficiency

ARSA "pseudodeficiency" occurs in 1-2% of European and Euro-American populations 1. These individuals have:

• 5-15% of normal ARSA enzymatic activity
• NO sulfatide excretion or pathologic storage
• NO clinical symptoms throughout life

This mandates that any positive biochemical test must be corroborated by a second test (ARSA gene sequencing or urinary sulfatide measurement) to distinguish true MLD from pseudodeficiency 1.

Histopathology

Cellular Pathology

The fundamental pathologic process involves moderate to massive accumulation of sulfated glycolipids, particularly galactosylceramide-3-O-sulfate (sulfatide), in the brain, peripheral nervous system, and kidneys 1.

Tissue distribution of sulfatide accumulation:

• Central nervous system: Progressive demyelination with white matter involvement
• Peripheral nervous system: Demyelination of peripheral nerves
• Kidneys: Sulfatide deposition
• Gallbladder: Papillomatous transformation visible on ultrasound 1

Ocular Histopathology

Electron microscopic studies demonstrate distinct patterns by disease subtype 5:

Infantile form shows:

• Storage of metachromatic complex lipids in retinal ganglion cells
• Involvement of optic nerve and ciliary nerves
• Mucopolysaccharide-like material in non-pigmented epithelium of ciliary body

Juvenile form shows:

• Lesions limited to optic, ciliary, and sensory nerves only

These morphological differences correlate with sulfatase A activity levels and explain variability in ocular manifestations 5.

Neuroimaging Correlates

Brain MRI demonstrates characteristic demyelination patterns 1:

• Early findings: Symmetric, non-enhancing periventricular and subcortical T2 white matter prolongation with arcuate fiber sparing and subcortical rim preservation
• Progressive findings: Cortical atrophy and ventriculomegaly

Clinical Manifestations

Classification by Age of Onset

MLD comprises a phenotypic continuum but is traditionally divided into three subtypes based on symptom onset 1:

Late Infantile MLD (40-60% of cases)

• Onset: 6 months to 4 years
• Course: Uniform disease progression, death within 5 years of onset
• Initial symptoms:
  • Peripheral neuropathy
  • Muscle weakness and appendicular hypotonia
  • Hypo- or areflexia
• Subsequent symptoms:
  • Mental regression
  • Visual and auditory impairment
  • Loss of ambulation with evolution to hypertonia
  • Dysarthria/ataxia
  • Bulbar paresis/dysphagia
  • Seizure disorder (25% of cases)
• End stage: Vegetative state, complete loss of interaction, death from aspiration pneumonia

Juvenile MLD (20-35% of cases)

• Onset: 4 to 16 years
• Course: More variable progression, death within 10-20 years of onset
• Initial symptoms:
  • Decline in school performance
  • Emotional and behavioral disturbances
  • Dysarthria/ataxia
  • Hyperreflexia
• Subsequent symptoms:
  • Mental regression
  • Optic atrophy
  • Loss of ambulation
  • Spastic quadriplegia
  • Incontinence
  • Bulbar paresis/dysphagia
  • Seizure disorder (50% of cases)
• End stage: Vegetative state and decerebrate posturing

Adult MLD (15-25% of cases)

• Onset: Following puberty (≥16 years)
• Course: Variable velocity of progression, death within 5-20 years of onset
• Initial symptoms:
  • Decline in school/job performance
  • Emotional lability
  • Disorganized thinking
  • Hallucinations/delusions (predominantly psychiatric presentation)
• Subsequent symptoms:
  • Clumsiness
  • Incontinence
  • Spastic quadriplegia
  • Choreiform movements and dystonia
  • Bulbar dysfunction
  • Seizures (rare)
• End stage: Vegetative state

Recent Understanding of Disease Progression

New data from 2025 demonstrate that presentation type significantly influences disease trajectory 6:

• Cognitive presentation: Much slower or even absent motor decline
• Mixed motor-cognitive presentation: Rapid motor decline

This represents an important refinement beyond traditional age-based classification and affects treatment timing decisions.

Diagnostic Laboratory Findings

Cerebrospinal fluid: Protein levels generally exceed 50 mg/dL in most cases except adult-onset type 1

Neurophysiologic studies 1, 7:

• Electromyography (EMG): Abnormal in 96% of patients with demyelinating sensorimotor neuropathy pattern
• Nerve conduction studies (NCS): Slowed velocities reflecting peripheral demyelination
• BAER and VER: Impairment of hearing and vision

Urinary sulfatides: Elevated in all MLD types (critical for distinguishing from pseudodeficiency) 1

Clinical Heterogeneity and Challenges

Important clinical variability exists 1:

• Juvenile and adult forms show considerable variability in presentation
• Some patients experience periods of disease stability punctuated by episodic deterioration
• Remarkable variability in severity even among patients with identical genotypes 4

The phenotypic continuum nature of MLD means that rigid age-based classification, while clinically useful, does not capture the full spectrum of disease presentations 1, 6.